SCHEMBL7704807

SCHEMBL7704807

CC1Oc2ccc(C(Cc3c(F)cccc3Cl)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.42
LMNA P02545 2/20 0.42
MITF O75030 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
SCN9A Q15858 2/20 0.37
CYP3A4 P08684 1/20 0.37
SMYD3 Q9H7B4 3/20 0.37
PARP1 P09874 3/20 0.36
KDR P35968 1/20 0.36
IDO1 P14902 1/20 0.35
KMT2A Q03164 1/20 0.35
DAO P14920 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7094067 0.91 HPGD (0.41) HSD17B10LMNAMITFMAPTHPGD
SCHEMBL7708055 0.87 PARP1 (0.41) HSD17B10MAPTHPGDHTTNPSR1
SCHEMBL7708086 0.87 CTSS (0.43) SCN9ASMYD3PARP1IDO1
SCHEMBL7713251 0.84 CTSS (0.45) HSD17B10LMNAHPGDMAPK1HTT
SCHEMBL7711137 0.84 CTSL (0.45) HSD17B10LMNAHPGDHTTNPSR1
SCHEMBL7713423 0.83 PARP1 (0.41) HSD17B10SMYD3PARP1KDRIDO1
SCHEMBL7713338 0.83 PARP1 (0.42) HSD17B10SMYD3PARP1KDRIDO1
SCHEMBL7708144 0.83 PARP1 (0.42) HSD17B10LMNAHPGDMAPK1HTT
SCHEMBL7713374 0.83 PARP1 (0.50) HSD17B10LMNAMAPTHPGDMAPK1
SCHEMBL7708210 0.83 MC4R (0.41) HSD17B10MAPTHPGDHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed